

References

R-6

1. Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. *Am J Neurodegener Dis*. 2013;2(1):29-34.
2. Siepel FJ, Rongve A, Buter TC, et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. *BMJ Open*. 2013;3(4):1-9.
3. NCCN clinical practice guidelines in oncology™: Prostate cancer (V.2.2014). National Comprehensive Cancer Network. Accessed 07/14/2014.
4. Davis PC, Wippold FJ II, Cornelius RS, et al. Expert Panel on Neurologic Imaging. ACR appropriateness criteria head trauma. Reston, VA. American College of Radiology (ACR). 2012.
5. Nissen T, Malek N, Grosset KA, et al. Baseline [123I] FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease. *Acta Neurol Scand*. 2014;129:204–208.
6. Jakobson S, Linder J, Forsgren L, et al. Accuracy of visual assessment of dopamine transporter imaging in early parkinsonism. *Movement Disorders*. 2014;8:1-7.
7. Sadasivan S, Friedman JH. Experience with DaTscan at a tertiary referral center. *Parkinsonism and Related Disorders*. 2014;42e-45.
8. Grosset DG, Tatsch K, Oertel WH, et al. Safety Analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123i injection (DaTscan). *J Nucl Med*. 2014;55(8):1-7.
9. Hauser RA, Bajaj N, Marek K, et al. Sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of DaTscan™ (ioflupane I123 injection): Predicting clinical diagnosis in early clinically uncertain parkinsonian syndrome. *J Neurol Stroke*. 2014;1(1):1-13.
10. Bajaj N, Hauser RA, Seibyl J, et al. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes. *Alzheimer's Research & Therapy*. 2014;6:67.
11. Gayed I, Joseph U, Fanous M, et al. The impact of DaTscan in the diagnosis of Parkinson disease. *Clin Nucl Med. Am J Manag Care*. 2015;40:390–393.
12. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson's disease. *Eur J Neurol*. 2013;20(1):16-34.
13. Cummings JL, Fine MH, Grachev IC, et al. Effective and efficient diagnosis of Parkinsonism: The role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™). Supplement to The American Journal of Managed Care. 2014;20(5):S97-S109.
14. Haraldsen A, Bluhme H, Rohl L, et al. Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer. *Clin Physiol Funct Imaging*. 2016;40–46.
15. Lascano AM, Perneger T, Vulliemoz S, et al. Yield of MRI, high-density electric source imaging (HD-ESI), SPECT and PET in epilepsy surgery candidates. *Clin Neuro*. 2016;150-155.

16. Sasaki M. SPECT findings in autism spectrum disorders and medically refractory seizures. *Epilepsy and Behav.* 2015;161-171.
17. Ramil N, Rahmat K, Lim KS, et al. Neuroimaging in refractory epilepsy. Current practice and evolving trends. *Eur J of Radiol.* 2015;1791-1800.
18. Rayment D, Biju M, Zheng R, et al. Neuroimaging in dementia; an update for the general clinician. *Progress NP.* 2016;16-20.
19. Sadasivan S, Friedman JH. Experience with DaTscan at a tertiary referral center. *Parkinsonism Relat Disord.* 2015;42-45.
20. Ba F, Martin W. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. *Parkinsonism Relat Disord.* 2015;87-94.
21. Haider HA, Hirsch LJ. Neuroimaging in the evaluation of seizures and epilepsy. *UpToDate.* 2014.
22. NICE Guidance. Dementia: supporting people with dementia and their carers in health and social care. National Institute for Health and Care Excellence. 2014.
23. ACR–SPR Practice parameter for the performance of single photon emission computed tomography (SPECT) brain perfusion and for brain death examinations. American College of Radiology. 2014.
24. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (¹²³I) ioflupane in diagnosis of parkinsonian syndromes. *J Neurol Neurosurg Psychiatry.* 2013;84(11):1288-1295.
25. Covington MF, Sherman S, Lewis D, Lei H, Krupinski E, Kuo PH. Patient survey on satisfaction and impact of 123I-Ioflupane Dopamine transporter imaging. Thomas B, ed. *PLoS ONE.* 2015;10(7):e0134457.
26. O'Brien JT, Oertel WH, McKeith IG, et al. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. *BMJ Open.* 2014;4(7):e005122.
27. Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T. Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? *Neurodegener Dis.* 2015;15:81-86.
28. National Institute for Health and Clinical Excellence (NICE). Parkinson's disease (update) [GID-CGWAVE0698]. 2016.
29. American College of Radiology College of Radiology (ACR). ACR Appropriateness Criteria®: Dementia and Movement Disorders. 2015.
30. Djang DSW, Janssen MJR, Bohnen N. SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0. 2011.
31. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. *Movement Disorders.* 2004;19(10):1175-1182.
32. Marshall VL, Reininger CB, Marquardt M, Patterson J, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year european multicenter study with repeat [123I]FP-CIT SPECT. *Movement Disorders.* 2009;24(4):500-508.

33. Oravivattanakul S, Benchaya L, Guiyun W, Ahmed A, et al. Dopamine transporter (DaT) scan utilization in a movement disorder center. *Movement Disorders Clinical Practice*. 2015;3(1):31-35.